Table 1.

Baseline Characteristics.

Total, N	13
Age at Diagnosis- yr: Median(Range)	62 (44–75)
Gleason score- no. (%)
7	4 (31)
8	1 (8)
9	4 (31)
10	1 (8)
Unknown	3 (23)
De Novo Amphicrine Disease, no. (%)	5 (38)
Treatment-Emergent Amphicrine Disease, no. (%)	8 (62)
Presented with metastatic disease at diagnosis (%)	5 (38)
Use of standard ADT no. (%)	13 (100)
Use of abiraterone, no. (%)	7 (54)
Use of enzalutamide, no. (%)	4 (31)
Use of docetaxel, no. (%)	7 (54)
Use of cabazitaxel, no. (%)	1 (8)
Use of taxane + platinum chemotherapy, no. (%)	4 (31)
Use of sipeleucel-T, no. (%)	3 (23)
Use of radium-223, no. (%)	1 (8)
Clinical Trial Participation, no. (%)*	4 (31)

^*Clinical Trials: Phase I Taiho TO-TASS3681–101 (NCT02566772) (Pt 2), Phase I DuoBody PSMA bispecific antibody (NCT03926013) (Pt 2), Phase II BAT + Olaparib (NCT03516812) (Pt 4), Phase II Bipolar Androgen Therapy (NCT02286921) (Pt 7), Inovio DNA Vaccine (NCT02514213) (Pt 14)